Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Tymlos Coverage Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentCignaPolicy IP0329

    Bone Modifiers - Tymlos

    Customize your policy alerts

    Sign up for Cigna Policy IP0329 alerts

    Get alerted when Policy IP0329 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity coverage for Tymlos subcutaneous injection for osteoporosis treatment in postmenopausal patients and men. Coverage is subject to the member's benefit plan, applicable law, and the clinical criteria in this policy.

    Policy Summary
    PayerCigna
    PolicyBone Modifiers - Tymlos
    Policy CodePolicy IP0329
    Change TypeUpdated
    Effective DateNov 15, 2026
    Last ReviewNov 5, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for Tymlos benefit coverage and document the applicable indication and criteria.
    SourceLink
    POLICY UPDATE CHANGES

    Bonsity was added to the preferred product criteria for Tymlos.

    A postmenopausal osteoporosis exception was added allowing the bisphosphonate trial requirement to be bypassed when the patient has a very low T-score below -3.0.

    The policy title was changed from Abaloparatide to Bone Modifiers - Tymlos.

    The concurrent-use exclusion was clarified to state that calcium and vitamin D supplements may be used with Tymlos.

    2 yearsMaximum total Tymlos therapy duration
    RequiredUtilization management requirement
    ≤ -2.5Qualifying osteoporosis threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    < -3.0Very-low-T-score exception
    Not coveredOsteoporosis prevention
    No changesLatest review status

    Covered and Noncovered Uses

    Employer-plan criteria

    Employer-plan criteria require all listed conditions.

    Employer-plan Tymlos coverage

    • Preferred teriparatide product trial: Patient has tried teriparatide pen (Forteo or generic), brand teriparatide, or Bonsity.
    • Cumulative duration: Patient has not received more than 2 years of cumulative Tymlos therapy.≤ 2 years

    Tymlos is not medically necessary for osteoporosis prevention. The policy covers treatment of qualifying osteoporosis, not use intended to prevent osteoporosis in patients without substantial bone loss.

    Concurrent use of Tymlos with other osteoporosis medications is not medically necessary. This includes oral or intravenous bisphosphonates, denosumab products, calcitonin nasal spray, teriparatide, and romosozumab. Calcium and/or vitamin D supplements may be used with Tymlos.

    Any use that does not meet the covered FDA-approved osteoporosis treatment criteria is considered not medically necessary. Requests must document a qualifying osteoporosis treatment indication and satisfy the applicable clinical, preferred-product, and duration requirements.

    Use beyond 2 years during a patient's lifetime is not recommended and is not approvable under the policy. Safety and efficacy have not been evaluated beyond 2 years; continuation or renewal may be approved only for the remaining portion of the cumulative lifetime limit.

    Initial Approval Requirements

    Employer-plan initial therapy

    Employer-plan initial approval requires the specified preferred-product trial and duration limit.

    Employer-plan initial therapy: Patient has tried teriparatide pen (Forteo or generic), brand teriparatide, or Bonsity and has not received more than 2 years of cumulative Tymlos therapy.≤ 2 years cumulative Tymlos therapy

    Continuation and Renewal

    Maximum cumulative therapy duration

    Continuation or renewal approval may be granted only for the remaining portion of the 2-year cumulative lifetime limit.

    Continuation duration: Total Tymlos exposure, including prior therapy, does not exceed 2 years during the patient's lifetime.2 years total

    Subtract prior Tymlos treatment from the approval duration; for example, 3 prior months permits 21 additional months.

    Required Prior Therapy

    StepRequired therapyAccepted exceptions and details
    1Try intravenous ibandronate or intravenous zoledronic acid (Reclast), or try at least one oral bisphosphonate or oral bisphosphonate-containing product.For the oral pathway, inadequate efficacy after a 12-month trial or significant intolerance is required. The requirement may also be met when the patient cannot swallow or remain upright after administration, has a pre-existing gastrointestinal condition, has severe renal impairment or chronic kidney disease, or has had an osteoporotic or fragility fracture. For postmenopausal patients, a very low T-score below -3.0 also permits bypass of the bisphosphonate trial.
    StepRequired preferred-product trialCoverage condition
    1Try teriparatide pen (Forteo or generic), brand teriparatide, or Bonsity before Tymlos.Approval is limited to patients who have not received more than 2 years of cumulative Tymlos therapy.

    Lifetime Quantity Limit

    Tymlos Maximum Therapy Duration
    Maximum cumulative durationUp to 2 years total during the patient's lifetime
    Continuation approvalOnly the remaining portion of the 2-year cumulative lifetime limit may be approved
    Prior exposure exampleThree prior months of Tymlos permits up to 21 additional months

    Clinical Thresholds and Treatment Parameters

    Osteoporosis T-Score
    Osteoporosis thresholdT-score at or below -2.5
    Qualifying measurement sitesLumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist)
    Measurement timingThe T-score may be current or from any time in the past
    Low Bone Mass T-Score
    Low bone mass rangeT-score between -1.0 and -2.5
    Qualifying measurement sitesLumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist)
    Measurement timing

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Tymlos. When approved, authorize only for the duration supported by the applicable criteria and remaining lifetime limit.

    • Approval may be granted for up to 2 years total during the patient's lifetime for qualifying osteoporosis treatment.
    • For a patient who has already used Tymlos, approve only the remaining duration (for example, 3 months used permits up to 21 additional months).
    Step Therapy

    Bisphosphonate Trial or Qualifying Exception

    Document the required prior osteoporosis therapy or the qualifying reason the patient cannot use it. The applicable pathway differs by indication and sex designation.

    • Postmenopausal patients: document a trial of intravenous ibandronate or zoledronic acid, or an oral bisphosphonate/bisphosphonate-containing product.
    • Men: document a trial of intravenous zoledronic acid or an oral bisphosphonate/bisphosphonate-containing product.

    Policy Definitions

    High Risk for Fracture
    Osteoporotic fracture historyA history of osteoporotic fracture qualifies as high risk for fracture
    Multiple risk factorsMultiple risk factors for fracture qualify
    Prior therapy failure or intoleranceFailure or intolerance of other osteoporosis therapy qualifies
    Low Bone Mass
    T-score rangeBetween -1.0 and -2.5
    Qualifying measurement sitesLumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist)
    Measurement timing

    Therapy Overview

    Tymlos (abaloparatide) is a human parathyroid hormone-related peptide analog and anabolic osteoporosis therapy that helps build bone. It is used to treat osteoporosis in postmenopausal patients and men who are at high risk for fracture, including patients with qualifying bone-density findings, osteoporotic or fragility fractures, low bone mass with high fracture risk, or limited ability to use other osteoporosis therapies. Tymlos is an option for patients unable to use oral bisphosphonate therapy and for patients at very high fracture risk. Calcium and vitamin D supplementation is recommended during treatment. Therapy is limited to 2 years total during the patient's lifetime because safety and efficacy have not been evaluated beyond that duration.

    Policy Summary
    PayerCigna
    PolicyBone Modifiers - Tymlos
    Policy CodePolicy IP0329
    Change TypeUpdated
    Effective DateNov 15, 2026
    Last ReviewNov 5, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for Tymlos benefit coverage and document the applicable indication and criteria.
    SourceLink
    On This Page
    Covered and Noncovered UsesInitial Approval RequirementsContinuation and RenewalRequired Prior TherapyLifetime Quantity LimitClinical Thresholds and Treatment ParametersAuthorization and Documentation RequirementsPolicy DefinitionsTherapy Overview
    The T-score may be current or from any time in the past
    Very Low T-Score Exception
    Very low T-scoreBelow -3.0
    Applicable populationPostmenopausal patients
    Policy exceptionPermits bypass of the bisphosphonate trial requirement
    Oral Bisphosphonate Trial
    Required trial duration12 months
    Inadequate efficacy examplesOngoing and significant loss of bone mineral density, no increase in BMD, or an osteoporotic or fragility fracture
    Alternative outcomeSignificant intolerance to an oral bisphosphonate, including severe gastrointestinal or musculoskeletal adverse events
    Severe Renal Impairment
    Creatinine clearance thresholdLess than 35 mL/minute
    Clinical categorySevere renal impairment
    Policy pathwaySevere renal impairment or chronic kidney disease may satisfy a bisphosphonate exception pathway
  1. An oral bisphosphonate trial must show either inadequate efficacy after 12 months or significant intolerance.
  2. An exception may be supported by inability to swallow, inability to remain upright after administration, a qualifying gastrointestinal condition, severe renal impairment/chronic kidney disease, an osteoporotic or fragility fracture, or a very low T-score where applicable.
  3. Step Therapy

    Employer-Plan Preferred Product Requirement

    For employer plans, document that the patient has tried a preferred teriparatide product before Tymlos. Approval is limited to the allowed duration and cumulative exposure.

    • Required preferred-product trial: teriparatide pen (Forteo or generic), brand teriparatide, or Bonsity.
    • Employer-plan approval may be granted for up to 2 years only when the preferred-product trial is documented.
    • Do not approve if the patient has received more than 2 years of cumulative Tymlos therapy.
    Documentation Required

    Clinical Eligibility Documentation

    Submit clinical documentation supporting an FDA-approved osteoporosis-treatment indication for a postmenopausal patient or for a man. The record must establish qualifying bone findings and the prescriber's assessment of fracture risk when applicable.

    • Document the treatment indication and prescriber information.
    • Document a current or historical T-score at or below -2.5 at the lumbar spine, femoral neck, total hip, and/or 33% (one-third) radius; or an osteoporotic or fragility fracture.
    • Alternatively, document low bone mass, such as a T-score between -1.0 and -2.5 at a listed site, together with the prescriber's determination that the patient is at high risk for fracture.
    • For men, the applicable criteria include a very low T-score or an osteoporotic/fragility fracture as specified in the policy.
    Documentation Required

    Prior Treatment and Exception Documentation

    Document the prior treatment history and the specific evidence supporting treatment failure, intolerance, or an exception to oral bisphosphonate therapy.

    • Identify the prior bisphosphonate product, route, and treatment duration.
    • For inadequate efficacy, document the prescriber's assessment after a 12-month oral-bisphosphonate trial and evidence such as ongoing significant BMD loss, no BMD increase, or an osteoporotic/fragility fracture.
    • For intolerance, document significant adverse effects, including severe gastrointestinal or musculoskeletal events.
    • For inability to use oral therapy, document dysphagia, inability to remain upright, or a qualifying gastrointestinal condition such as an esophageal lesion, ulcer, stricture, or achalasia.
    • For the renal exception, document severe renal impairment or chronic kidney disease; a policy example is creatinine clearance below 35 mL/minute.
    Documentation Required

    Duration and Preferred-Product Documentation

    Document both the requested duration and all prior Tymlos exposure, including employer-plan preferred-product history when applicable. The request must remain within the patient's lifetime limit.

    • Report cumulative lifetime Tymlos use and subtract prior treatment from the requested approval period.
    • Do not request or approve more than 2 years of total Tymlos therapy during the patient's lifetime.
    • For employer plans, document the required trial of teriparatide pen (Forteo or generic), brand teriparatide, or Bonsity before Tymlos.
    • Employer-plan approval is limited to up to 2 years and is not permitted when cumulative Tymlos exposure already exceeds 2 years.
    Denial Risk

    Noncovered Indication

    Tymlos is not medically necessary for osteoporosis prevention or other uses that do not meet the policy's qualifying osteoporosis-treatment criteria.

    • Do not submit Tymlos for prevention in a patient without substantial bone loss; the policy states that this population has not been adequately studied.
    • Other nonqualifying or non-covered uses are not eligible for coverage.
    Denial Risk

    Concurrent Osteoporosis Medication Exclusion

    Do not use Tymlos concurrently with another medication for osteoporosis. Calcium and/or vitamin D supplements may be used with Tymlos.

    • Avoid concurrent oral bisphosphonates such as alendronate, risedronate, or ibandronate.
    • Avoid concurrent intravenous bisphosphonates, including zoledronic acid (Reclast) and intravenous ibandronate.
    • Avoid concurrent denosumab products, calcitonin nasal spray, teriparatide products, and Evenity (romosozumab-aqqg).
    • Calcium and vitamin D supplementation is permitted with Tymlos.
    Denial Risk

    Lifetime Duration Limit

    Requests exceeding 2 years of cumulative lifetime Tymlos therapy do not meet the policy. Confirm prior exposure before submitting an initial or renewal request.

    • Safety and efficacy have not been evaluated beyond 2 years, and use beyond 2 years during a patient's lifetime is not recommended.
    • Include prior Tymlos dates and total duration; reduce the requested approval period by previously completed therapy.
    • Employer-plan requests are also subject to this cumulative lifetime limit.
    Denial Risk

    Unmet Medical Necessity Criteria

    Coverage may be denied when the documented indication, bone findings, prior-treatment requirement, exception evidence, renal criterion, preferred-product requirement, duration limit, or other applicable criterion is not met.

    • Denial risk includes failure to document qualifying T-score, osteoporotic/fragility fracture, or low bone mass plus prescriber-determined high fracture risk.
    • Denial risk includes failure to establish the required bisphosphonate trial, inadequate efficacy, significant intolerance, inability to take oral therapy, or qualifying renal impairment.
    • Denial risk includes nonqualifying prevention or other use, concurrent osteoporosis medication use, or a request beyond 2 years of cumulative lifetime Tymlos therapy.
    • For employer plans, denial risk includes failure to try a listed preferred teriparatide product.
    The T-score may be current or from any time in the past
    Men
    Policy definitionIndividuals with the biological traits of a man
    Gender identityThe definition applies regardless of gender identity
    Gender expressionThe definition applies regardless of gender expression